Most clinical trial supply failures aren’t manufacturing failures. They’re distribution failures. Warehousing failures. Framework confusion failures. And they’re almost always preventable if GxP is designed in at the protocol stage, not bolted on after site activation.
I’ve spent years working at the intersection of Quality, Supply Chain, and Operations in global clinical trials. The pattern I keep seeing sponsors and CROs treat GxP compliance as a supplier problem. It isn’t. It’s a shared obligation, and the decisions made during protocol design determine whether your supply chain holds up under inspection.
Here’s what GMP, GDP, and GWP actually mean in practice, and where the compliance gaps consistently appear.
GxP is not one standard. It’s a family of them.
The “x” is a domain variable: Manufacturing (GMP), Distribution (GDP), Warehousing (GWP), Clinical Practice (GCP), Laboratory Practice (GLP), and others.
Each framework protects product quality and patient safety. Each applies at a different point in the lifecycle. And, each carries its own documentation requirements, audit trail obligations, and inspection exposure.
In global clinical trial supply, GMP and GDP are in scope across all jurisdictions. GWP applies as a distinct, standalone framework primarily in Australia; in most other markets, warehousing obligations are embedded within the GDP framework.
They are additive obligations, not overlapping ones.
Good Manufacturing Practice, where the product is made and released
GMP governs consistency. Every batch of an IMP or comparator is produced to meet the same phase-appropriate process, documented to the same standard, released against the same quality criteria, including batch record review, yield reconciliation, and release.
For clinical trial supply, IMP manufacturing and repackaging is governed by Annex 13 of the PIC/S Guide to GMP. Most major regulatory authorities globally — including TGA, PMDA, EMA, and Health Canada — align with the same PIC/S standard.
Any organisation manufacturing, repackaging, or relabelling an IMP or commercially available comparator must hold the appropriate manufacturing licence for the jurisdiction where that activity occurs. This is the operative standard for investigational medicinal product manufacture in Australia, and the benchmark most regulatory authorities align with.
Good Distribution Practice where the product moves, and where it is stored post-release
GDP governs the storage, handling, and movement of medicinal products through the distribution.
GDP governs integrity across the entire post-certification supply chain, storage of released product, cold chain logistics, validated containers, continuous monitoring, and documented deviation management.
This is where most clinical supply failures happen.
An excursion from specified temperature conditions must be documented, assessed against product stability data, and resolved through a formal quality decision before the affected product is released for use. A verbal confirmation does not satisfy the requirement. A retrospective note does not satisfy the requirement.
The operative global benchmark for finished medicinal product GDP compliance is the EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01), adopted or mirrored by many regulatory authorities globally. These guidelines codify the requirements that define Akesa’s distribution obligations:, documented temperature excursion management, change-of-custody controls, and auditable evidence of product integrity at every point of transfer.
The regulatory direction is clear, and it is being enforced, not relaxed.
Good Warehousing Practice: warehousing obligations within and beyond Australia
In most jurisdictions globally, warehousing requirements, receipt, inspection, storage, batch segregation, quarantine, label reconciliation, and preparation for dispatch are governed within the GDP framework. There is no separately codified GWP standard; GDP covers these activities.
In Australia, the TGA applies GWP as a distinct operational framework alongside GDP, with its own documented requirements for validated storage environments, continuous temperature and humidity monitoring, segregation and quarantine procedures, and written SOPs for every warehouse activity.
For Akesa’s Australian operations, both GDP and GWP obligations apply simultaneously. For our global operations across other jurisdictions, the equivalent warehousing controls are met through GDP compliance.
The documentation obligation, regardless of which framework applies in a given jurisdiction, is continuous. Periodic spot checks do not satisfy it.
Recurring compliance gaps. Meeting one framework does not establish compliance with the others. This is not a subtle point — but inspection findings suggest it is still being missed.
Between July and December 2025, the FDA issued 327 Warning Letters, a 73% increase on the same period in 2024, according to Reed Smith LLP’s analysis of the FDA Compliance Dashboard. In Australia, the TGA’s GCP Inspection Program Report for 2023–2024 found deficiencies in investigational product management in 7 of 12 routine inspections, with the most common issues in supplying, storage, retrieval, and destruction.
GDP and GWP failures. Not GMP failures.
A product can be GMP-compliant at QP/AP certification and still fail GDP in storage or transit. It can have intact GDP records and still fail warehousing requirements inside the depot. Each framework has its own audit trail. Each has its own inspection exposure. They are designed to be applied together.
Global Trials compounding complexity
In a single-country trial, managing these frameworks is demanding but tractable. In multi-regional trials, spanning regulatory authorities including the FDA, EMA, TGA, PMDA, NMPA, HSA, and others, the complexity multiplies.
Each authority enforces its own interpretation of these standards. Documentation requirements differ. Import permit conditions differ. Cold chain validation expectations differ. Inspection approaches differ.
Countries require local data from clinical trials for regulatory approval, which means the supply chain must be configured to meet those country-specific standards from the outset, not retrofitted after activation.
The practical implication is that GxP compliance cannot be designed generically for a trial and applied uniformly across countries. Each jurisdiction requires a review of which specific requirements apply to each supply chain activity taking place within it.
At Akesa, we operate across this regulatory landscape globally. What that means in practice: GxP compliance cannot be designed once and applied uniformly. Each jurisdiction requires a review of which specific requirements apply to each supply chain activity taking place within it, and that review needs to happen before a single site is activated.
The questions are worth asking at protocol design, not after
This is where the cost of getting it wrong is lowest.
- Which regulatory frameworks govern each supply component in each participating country?
- What are the import permit requirements and lead times per jurisdiction?
- What temperature validation and stability data coverage is required across all planned transit routes?
- Where does QP/AP release apply, and which entity holds the relevant licence for each country?
- What are the GDP deviation management requirements for each jurisdiction’s competent authority?
- Where GWP applies as a distinct framework (e.g. Australia), are warehousing SOPs documented to that standard separately from GDP?
Sponsors and CROs who ask these questions at the design phase spend less time resolving compliance issues after activation.
GxP compliance is not a post-activation problem to solve. It is a protocol design input. The frameworks are established. The inspection expectations are clear. The question for every sponsor and CRO entering a multi-country trial is whether the supply chain has been designed to meet those expectations in each jurisdiction from the outset, or whether that work has been deferred to a point in the trial when delay is no longer an option.
The content published on this website is provided for general information purposes only. It does not constitute regulatory, legal, clinical, financial, or professional advice. Akesa makes no representation that the content is current, complete, or applicable to any specific situation. Readers should seek appropriate professional advice before acting on any information published on this site. Content reflects Akesa’s view at the date of publication and may be updated without notice.
